Latest news with #Lenalidomide
The Citizen
4 days ago
- Health
- The Citizen
Local man fights rare cancer with hope and strength
Gregory Morgan from Kibler Park is facing the biggest challenge of his life after being diagnosed with a rare form of cancer. Morgan was diagnosed with multiple myeloma on February 28, 2022, at the Milpark Hospital. Now, he is asking for community support to help cover the high costs of life-saving treatment. A sudden turn 'Morgan's journey began in January 2022 when admitted to Mulbarton Hospital with a chest infection. During his stay, he contracted the Pseudomonas virus, a serious bacterial infection. Though treated and discharged, he soon returned with the same infection. During his stay, he picked up the pseudomonas virus, a serious bacterial infection. Although treated and discharged, he soon found himself back in the hospital with the same infection. 'I had a biopsy done on my lungs to check for cancer, but thankfully, it came back negative,' said Morgan. 'I was put on antibiotics and discharged again, but just a week later, I was back in the hospital.' On February 19, 2022, he was admitted to the Milpark Hospital in critical condition. 'I became extremely sick. My C-reactive protein (CRP) level was 591, so I was put in the ICU for nearly three weeks,' he said. Under the care of Dr PG Williams, further investigations revealed a possible diagnosis of multiple myeloma, a type of blood cancer. An oncologist later confirmed this after a bone marrow biopsy. Morgan began chemotherapy shortly afterwards and in April 2023, was approved for an autologous stem cell transplant. 'It works by using your healthy stem cells and is a 100% match. I didn't require a donor,' he explained. The first step involved harvesting his healthy stem cells, followed by a high-dose chemotherapy regimen to eliminate cancer cells. The stem cells were then re-infused, allowing them to migrate back into his bone marrow. Thereafter, his good stem cells were re-infused and migrated into his bone marrow. 'This was an unpleasant experience, but it also gave me hope for my recovery. After my transplant, I needed to continue with oral chemotherapy treatment for almost three years.' Unfortunately, in October last year, he suffered a relapse. Morgan was given stronger oral chemotherapy drugs and monitored by his oncologist monthly. At this time, he also suffered from severe back and nerve pain and had to have a spinal fusion, but couldn't while on chemotherapy. 'January this year, my cancer cells continued to increase. My oncologist advised me that I needed to start with a combination of even stronger chemotherapy. This devastating news again emotionally affected me. My chemo drugs were stopped for almost two months so I could have my spinal fusion procedure done on March 4,' explained Morgan. The fight begins He is now undergoing a new round of intense treatment, a combination of Ninlarb, Lenalidomide, and Neofordex, which he started in March. These medications are necessary to control cancer but come with a steep price. 'The cost of my current treatment is almost R50 000 monthly. My medical aid doesn't cover everything, and once the oncology benefit runs out, I have to pay the rest out of pocket,' he explained. His oncologist advised him that this treatment would be long-term, two to three years, with bone marrow biopsies every six months. Hope beyond donations Despite the hardships, Morgan remains hopeful and deeply motivated by his love for his family. 'What keeps me going is the hope of spending more time with my grandchildren. It's not just about me; it's about giving myself the best shot at life.' In a heartfelt plea, Morgan said he has always tried to be strong and handle things alone, but this diagnosis forced him to ask for help. 'The weight, physically, emotionally, and financially, became too heavy to carry by myself,' he said. 'Asking for help hasn't been easy, but it's necessary. If people in the community respond to my appeal, it would mean more than just financial help; it would mean hope,' emphasised Morgan. He wants to remind others facing battles that they are not alone. 'To anyone in a difficult season, I want to say: There is hope. You might feel like the weight is too heavy but know there is light on the other side. Hold onto hope with both hands.' As he continues his fight against cancer and with his faith in God and prayer, Morgan is making a heartfelt appeal to the public. 'I am personally asking for help,' he said. 'Your donation, no matter how small, can help me cover these costs and continue my fight against cancer.' With the support of the community, he hopes to alleviate the financial pressure so he can focus on his recovery and spend time with his loved ones. 'Your support would mean the world to me. If you're able to donate or even share my story, you'll be making a real difference in my life,' Morgan added. 'It's not just about the money. It's about giving me the strength to keep going and the chance to live a fulfilling life again.' Those wanting to support Morgan can visit his fundraising page or make a direct donation to: Discovery Bank; GN Morgan; Account No: 1832 7837 521; He is also running a Father's Day raffle, with prizes sponsored by Detailease. The details are on his Facebook and TikTok pages. Every act of kindness brings Morgan one step closer to hope and healing. At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
Business Wire
6 days ago
- Business
- Business Wire
Deadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming June 3, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Viatris Inc. ('Viatris' or the 'Company') (NASDAQ: VTRS) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON VIATRIS INC. (VTRS), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On December 23, 2024, Viatris disclosed that 'following an inspection by the U.S. FDA' at the Company's manufacturing facility in Indore 'the Agency has issued a Warning Letter, and an Import Alert related to this facility' which 'affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted.' Then, on February 27, 2025, Viatris released its fourth quarter and full year 2024 financial results, reporting, among other things, financial guidance metrics for fiscal year 2025 with 'anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA.' On this news, Viatris' stock price fell $1.71, or 15.2%, to close at $9.53 per share on February 27, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Viatris' efforts to downplay the ramifications of the Indore facility's failed FDA inspection fell short of reality; (2) the impact to the Company's projected fiscal year 2025 finances from the combination of the ongoing remediation efforts at the facility, the inability for the facility to manufacture and ship key products for the Company, particularly Lenalidomide, the inability for Viatris to convince the FDA to expand the exempt list to include such drugs, and an associated impact on shipments to other regions from the Indore facility was significant and resulted in much more than 'a little bit' of a headwind; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Viatris securities between August 8, 2024, to February 26, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is June 3, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Upturn
25-05-2025
- Business
- Business Upturn
VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)
NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al. , No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Associated Press
21-05-2025
- Business
- Associated Press
VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Business Upturn
17-05-2025
- Business
- Business Upturn
VTRS SHAREHOLDER NEWS: Investors of Viatris Inc. Securities are Reminded of the June 3 Class Action Deadline — Contact BFA Law (NASDAQ:VTRS)
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al. , No. 25-cv-466. Why was Viatris Sued for Securities Fraud? Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in 'good operating condition,' were 'suitable for their intended purposes,' and that the Company was 'committed to maintaining the highest quality manufacturing standards.' However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company's Indore, India, facility. Still, Viatris downplayed the situation, describing it as a 'little bit of headwind' and spoke about 'active discussions with the FDA' to get additional products produced at the facility exempted from the FDA's Import Alert. In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company's financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide. The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the 'negative impact' of the Indore facility's failed inspection would lower 2025 revenue by 'approximately $500 million' and 2025 earnings from operations by 'approximately $385 million.' The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025. Click here if you suffered losses: What Can You Do? If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
